Reflection on my time on the NMBI Registration Committee
In December my second and final term as a member of the NMBI will come to an end. For the last five years I have been both a member and the Chairman of the Registration Committee, and now that my tenure is concluding, I want to reflect some of the many matters that the committee has considered during that time.
Read more
|
|
|
|
MyNMBI is LIVE!
On Monday, 28 September MyNMBI, our new online registration system launched as planned. Students and recent graduates have been the first users of the system. As a result of these initial interactions we continue to make tweaks and also consider our escalation process for those who need help. Over the next number of months we have a programme of high vigilance in place to continue to support users as more of you start to use the system.
Read more
|
| |
| |
Board Elections for 2020 - Three Candidates Elected
The poll to elect three registrants to be members of the Board of NMBI closed on Wednesday, 23 September 2020 at noon.
The successful candidates in the three categories were:
Category 1: A registered nurse from the practice of general nursing engaged in clinical practice Joseph Shalbin Kallarakkal
Category 2: A registered nurse from the practice of children's nursing Marian Vaughan
Category 3: A registered nurse or a registered midwife employed in the public health sector and engaged in the education of nurses and midwives Lorraine Clarke-Bishop
Read more
|
| |
HPRA - Information Update on Medicines from HPRA
|
The 99th edition of the HPRA Drug Safety Newsletter includes information on the following medicines:
- Erythromycin – Updated warnings regarding cardiovascular risks and infantile hypertrophic pyloric stenosis
- Vascular Endothelial Growth Factor (VEGF) pathway inhibitors – Risk of aneurysm and artery dissection
- Implanon NXT (etonogestrel implant) – Updated insertion and removal instructions due to risk of neurovascular injury and implant migration
- Insulin-containing medicines – Risk of cutaneous amyloidosis and potential for associated changes in glycaemic control
- Leuprorelin-containing depot medicines – Risk of lack of efficacy due to incorrect reconstitution and administration
- Xeljanz ▼(tofacitinib) – Updated recommendations due to increased risk of venous thromboembolism and serious and fatal infections
- Risk of respiratory depression and sedation associated with Epaclob 1mg/ml and 2mg/ml oral suspension (clobazam)
For further details please visit the HPRA website.
Read more
|
|
|
|
|
|